

## Mektovi® (binimetinib) (Oral)

Document Number: IC-0373

Last Review Date: 10/28/2019

Date of Origin: 08/02/2018

Dates Reviewed: 08/2018, 10/2018, 11/2019

### I. Length of Authorization

Coverage is provided for six months and may be renewed.

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [Pharmacy Benefit]:

- Mektovi 15 mg tablet: 6 tablets per day

#### B. Max Units (per dose and over time) [Medical Benefit]:

- 90 mg daily

### III. Initial Approval Criteria

Coverage is provided in the following conditions:

- Baseline left ventricular ejection fraction (LVEF) within normal limits; **AND**
- Patient is at least 18 years or older; **AND**
- Patient has not received prior therapy with BRAF and/or MEK inhibitors (e.g., vemurafenib, dabrafenib, cobimetinib, trametinib, etc.) unless otherwise specified; **AND**

#### Melanoma †

- Patient must have BRAF V600 E or K mutation as detected by FDA approved test\*; **AND**
- Patient has not received more than one prior line of PD-1 monotherapy and PD-1/CTLA-4 combination therapy for unresectable locally advanced or metastatic disease; **AND**
- Patient does not have leptomeningeal metastases or other untreated CNS lesions; **AND**
- Used as in combination with encorafenib for patients with unresectable locally advanced or metastatic melanoma; **AND**
  - Used as initial therapy or subsequent therapy; **OR**
  - Used as re-induction therapy for progression/relapse in patients who had disease control for >3 months after previous therapy with binimetinib ‡

## Colorectal Cancer ‡

- Patient has BRAF V600E mutation; **AND**
- Used in combination with encorafenib **AND** either cetuximab or panitumumab; **AND**
- Used as subsequent therapy after progression of unresectable or metastatic disease (no prior cetuximab/panitumumab); **AND**
  - Patient was previously treated with an irinotecan- or oxaliplatin-based therapy; **OR**
  - A fluoropyrimidine-based therapy without irinotecan or oxaliplatin followed by FOLFOX or CapeOX

\*<http://www.fda.gov/CompanionDiagnostics>

† FDA Approved Indication(s); ‡ Compendia Approved Indication(s)

## IV. Renewal Criteria

Coverage can be renewed based upon the following criteria:

- Patient continues to meet the criteria identified in Section III; **AND**
- Tumor response with stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: interstitial lung disease/pneumonitis, cardiomyopathy; severe hemorrhagic events, venous thromboembolism, ocular toxicities including retinal vein occlusion (RVO), rhabdomyolysis, etc. **AND**
- Left ventricular ejection fraction (LVEF) has not had an absolute decrease from baseline  $\geq$  10% and is not below the lower limit of normal (LLN)

### Melanoma (metastatic or unresectable disease)

- Patient has completed initial induction; **AND**
- Used as re-induction therapy in patients who experienced disease control, but subsequently disease progression/relapse > 3 months after treatment discontinuation; **AND**
- Used in combination with encorafenib

## V. Dosage/Administration

Indication	Dose
All indications	45 mg orally twice daily without regard to food

## VI. Billing Code/Availability Information

HCPCS code:

- J8999 – Prescription drug oral, chemotherapeutic, Not Otherwise Specified
- C9399 – Unclassified drugs or biologics (Hospital Outpatient Use Only)

## NDC:

- Mektovi 15 mg tablet: 70255-0010-xx

## VII. References

1. Mektovi [package insert]. Boulder, CO; Array BioPharma; January 2019. Accessed October 2019.
2. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. *N Engl J Med.* 2012 Jul 12; 367(2):107-14.
3. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N Engl J Med.* 2012 Nov; 367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29.
4. Long GV, Stroyakovksy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *N Eng J Med* 2014 Sep 29, [Epub ahead of print]
5. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) binimetinib. National Comprehensive Cancer Network, 2019. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed October 2019.
6. Dummer R, Ascierto PA, Gogas H, et al. Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma (Abstract 9504). American Society of Clinical Oncology 2018 annual meeting.
7. Van Cutsem E, Huijberts S, Grothey A, et al. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. *J Clin Oncol.* 2019 Jun 10;37(17):1460-1469.

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C17.0	Malignant neoplasm duodenum
C17.1	Malignant neoplasm jejunum
C17.2	Malignant neoplasm ileum
C17.8	Malignant neoplasm of overlapping sites of small intestines
C17.9	Malignant neoplasm of small intestine, unspecified
C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon

ICD-10	ICD-10 Description
C18.3	Malignant neoplasm of hepatic flexure
C18.4	Malignant neoplasm of transverse colon
C18.5	Malignant neoplasm of splenic flexure
C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.8	Malignant neoplasm of overlapping sites of large intestines
C18.9	Malignant neoplasm of colon, unspecified
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C43.0	Malignant melanoma of lip
C43.10	Malignant melanoma of unspecified eyelid, including canthus
C43.11	Malignant melanoma of right eyelid, including canthus
C43.12	Malignant melanoma of left eyelid, including canthus
C43.20	Malignant melanoma of unspecified ear and external auricular canal
C43.21	Malignant melanoma of right ear and external auricular canal
C43.22	Malignant melanoma of left ear and external auricular canal
C43.30	Malignant melanoma of unspecified part of face
C43.31	Malignant melanoma of nose
C43.39	Malignant melanoma of other parts of face
C43.4	Malignant melanoma of scalp and neck
C43.51	Malignant melanoma of anal skin
C43.52	Malignant melanoma of skin of breast
C43.59	Malignant melanoma of other part of trunk
C43.60	Malignant melanoma of unspecified upper limb, including shoulder
C43.61	Malignant melanoma of right upper limb, including shoulder
C43.62	Malignant melanoma of left upper limb, including shoulder
C43.70	Malignant melanoma of unspecified lower limb, including hip
C43.71	Malignant melanoma of right lower limb, including hip
C43.72	Malignant melanoma of left lower limb, including hip
C43.8	Malignant melanoma of overlapping sites of skin
C43.9	Malignant melanoma of skin, unspecified
C78.00	Secondary malignant neoplasm of unspecified lung
C78.01	Secondary malignant neoplasm of right lung

ICD-10	ICD-10 Description
C78.02	Secondary malignant neoplasm of left lung
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
Z85.038	Personal history of other malignant neoplasm of large intestine
Z85.068	Personal history of other malignant neoplasm of small intestine

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC